Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for human epidermal growth factor receptor 2 (HER2)‑positive, unresectable, locally advanced or metastatic breast cancer in adults who have had trastuzumab and a taxane.
A table of NHS England interim treatment regimens gives possible alternative treatment options for use during the COVID-19 pandemic to reduce infection risk. This may affect decisions on using trastuzumab emtansine. See the COVID-19 rapid guideline: delivery of systemic anticancer treatments for more details.
In November 2017, this guidance was amended after a change to the commercial arrangements in October 2017. This change does not affect the cost effectiveness of trastuzumab emtansine. Sections 1, 2 and 5.4 have been updated.
Is this guidance up to date?
Next review: 2020
Guidance development process
This guidance is a Cancer Drugs Fund reconsideration of trastuzumab emtansine for the treatment of HER2-positive, unresectable, locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane (TA371). This guidance replaces TA371.
The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to take this guidance fully into account, alongside the individual needs, preferences and values of their patients. The application of the recommendations in this guidance is at the discretion of health professionals and their individual patients and do not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.
All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.
Commissioners and/or providers have a responsibility to provide the funding required to enable the guidance to be applied when individual health professionals and their patients wish to use it, in accordance with the NHS Constitution. They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.